IL314467A - Lymphatic releasing fatty acid preparations and their uses for lymphatic inclusion and treatment of systemic disease - Google Patents

Lymphatic releasing fatty acid preparations and their uses for lymphatic inclusion and treatment of systemic disease

Info

Publication number
IL314467A
IL314467A IL314467A IL31446724A IL314467A IL 314467 A IL314467 A IL 314467A IL 314467 A IL314467 A IL 314467A IL 31446724 A IL31446724 A IL 31446724A IL 314467 A IL314467 A IL 314467A
Authority
IL
Israel
Prior art keywords
lymphatic
lymph
incorporation
fatty acids
disease treatment
Prior art date
Application number
IL314467A
Other languages
English (en)
Hebrew (he)
Inventor
Richard Preston Mason
Richard Louis Dunbar
Original Assignee
Amarin Pharmaceuticals Ie Ltd
Richard Preston Mason
Richard Louis Dunbar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Pharmaceuticals Ie Ltd, Richard Preston Mason, Richard Louis Dunbar filed Critical Amarin Pharmaceuticals Ie Ltd
Publication of IL314467A publication Critical patent/IL314467A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL314467A 2022-01-26 2023-01-26 Lymphatic releasing fatty acid preparations and their uses for lymphatic inclusion and treatment of systemic disease IL314467A (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202263303383P 2022-01-26 2022-01-26
US202263303365P 2022-01-26 2022-01-26
US202263304042P 2022-01-28 2022-01-28
US202263334071P 2022-04-22 2022-04-22
US202263334065P 2022-04-22 2022-04-22
US202263340304P 2022-05-10 2022-05-10
US202263340292P 2022-05-10 2022-05-10
US202263342509P 2022-05-16 2022-05-16
US202263348908P 2022-06-03 2022-06-03
PCT/US2023/011651 WO2023146984A1 (en) 2022-01-26 2023-01-26 Lymph-releasing compositions of fatty acids and uses thereof for lymphatic incorporation and systemic disease treatment

Publications (1)

Publication Number Publication Date
IL314467A true IL314467A (en) 2024-09-01

Family

ID=87472560

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314467A IL314467A (en) 2022-01-26 2023-01-26 Lymphatic releasing fatty acid preparations and their uses for lymphatic inclusion and treatment of systemic disease

Country Status (10)

Country Link
US (1) US20240165066A1 (https=)
EP (1) EP4468884A4 (https=)
JP (1) JP2025503961A (https=)
KR (1) KR20240142470A (https=)
AU (1) AU2023213684A1 (https=)
CA (1) CA3248854A1 (https=)
IL (1) IL314467A (https=)
MA (1) MA66915A1 (https=)
MX (1) MX2024009147A (https=)
WO (1) WO2023146984A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3278665T (pt) * 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
US12433864B2 (en) 2019-06-03 2025-10-07 Migal Galilee Research Institute Ltd. 5,6-diHETE lactone for treatment of microvascular dysfunction
GB202400712D0 (en) * 2024-01-18 2024-03-06 Northwood Consultants Ltd Anti-inflammatory composition and use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069322A (en) * 1958-05-28 1962-12-18 Bergstrom Sune Pge and pgf
SE8604117D0 (sv) * 1986-09-29 1986-09-29 Kabivitrum Ab Composition
US5262168A (en) * 1987-05-22 1993-11-16 The Liposome Company, Inc. Prostaglandin-lipid formulations
US5262437A (en) * 1990-12-10 1993-11-16 Allergan, Inc. Homo-prostaglandin derivatives as ocular hypotensives
US6077525A (en) * 1998-04-10 2000-06-20 The George Washington University Use of conjugated linoleic acids
JP2005529728A (ja) * 2002-06-18 2005-10-06 マーテック・バイオサイエンシーズ・コーポレーション 水溶液中の油の安定エマルジョンおよびその製造方法
TWI365716B (en) * 2003-12-02 2012-06-11 Suntory Holdings Ltd Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20070042008A1 (en) * 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
US20090320148A1 (en) * 2006-01-31 2009-12-24 Martek Biosciences Corporation Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
ATE549014T1 (de) * 2006-09-05 2012-03-15 Q P Corp Prostaglandin-fettemulsion, verfahren zu ihrer herstellung, verfahren zu ihrer stabilisierung und emulgierendes mittel
WO2011060084A1 (en) * 2009-11-10 2011-05-19 MyCell Holdings Limited Stabilized formulations of fatty acids
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
MX372724B (es) * 2012-12-24 2020-06-19 Qualitas Health Inc Formulaciones de acido eicosapentaenoico (epa).
MY185428A (en) * 2015-01-21 2021-05-19 Mochida Pharm Co Ltd Self-emulsifying composition of ?-3 fatty acid
CA2974495C (en) * 2015-01-21 2023-05-23 Mochida Pharmaceutical Co., Ltd. .omega.-3 fatty acid self-emulsifying composition
JP6783891B2 (ja) * 2019-04-10 2020-11-11 持田製薬株式会社 ω３脂肪酸の自己乳化組成物

Also Published As

Publication number Publication date
US20240165066A1 (en) 2024-05-23
EP4468884A4 (en) 2025-12-10
EP4468884A1 (en) 2024-12-04
AU2023213684A1 (en) 2024-08-15
KR20240142470A (ko) 2024-09-30
MX2024009147A (es) 2024-08-06
CA3248854A1 (en) 2023-08-03
MA66915A1 (fr) 2025-10-31
JP2025503961A (ja) 2025-02-06
WO2023146984A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
IL314467A (en) Lymphatic releasing fatty acid preparations and their uses for lymphatic inclusion and treatment of systemic disease
EP4284188A4 (en) MEAT SUBSTITUTE COMPOSITION CONTAINING SATURATED STEARIC ACIDS AND LAURIC ACID RESIDUES
CN1636577A (zh) 阴道护理组合
WO2009091538A3 (en) Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia
HUP0303881A3 (en) Pharmaceutical compositions containing fatty alcohols and fatty acid esters useful for treatment of inflammation
EE05320B1 (et) Eikosapentaeenhappe etlestri ja dokosaheksaeenhappe etlestri segu sisaldava essentsiaalse rasvhappe kasutamine
WO2007124598A3 (en) Softgel capsules with phytosterols and/or phytostanols and optionlly omega polyunstaurated fatty acids
EP4121077A4 (en) COMPOSITIONS AND METHODS FOR TREATING SOLID AND SOFT TUMORS AND PROLIFERATIVE DISEASES
WO2006111633A3 (fr) Utilisation de la lecithine comme medicament dans le traitement du psoriasis
GEP20146088B (en) Pharmaceutical composition including docosahexaenoic acid (dha) ester to be parenterally administered
ATE338556T1 (de) Dihydrotriterpene bei der behandlung von virusinfektionen, herz und kreislauf krankheiten, entzündungen, überempfindlichkeiten oder schmerzen
EP4099997A4 (en) METHODS AND COMPOSITIONS FOR TREATING DISEASES
EP4341380A4 (en) TERPENE ALCOHOL FATTY ACID ESTERS
JP2011520883A5 (https=)
IL326143A (en) Use of Welling's formulation for the preparation of a medicament for the treatment or prevention of non-alcoholic fatty liver disease
AU2021347431B2 (en) Method of treating fatty liver disease
PH12020550961A1 (en) Stabilizing omega-3 fatty acids with bran
PL4094757T3 (pl) Kompozycja acyloetanoloamidów z kwasów tłuszczowych oliwy z oliwek
GB202409642D0 (en) Cannabinoid and omega fatty acid compositions and methods of using
US20140205650A1 (en) Coated suppositories
HK40108942A (en) Mixture of monobranched and polybranched fatty acids
GB202102261D0 (en) Compositions and methods relating to the treatment of diseases
CA3282604A1 (en) Use of fatty acids to modify flavor
MX2023006727A (es) Esteres de acidos dicarboxilicos para el tratamiento de enfermedades y padecimientos asociados con la toxina fosfolipasa d.
KR102282638B9 (ko) 베이지 지방세포 및 갈색 지방세포 분화조절용 조성물, 분화 유도방법, 및 이를 포함한 체지방 감소 및 비만 예방용 약학 조성물